Effects of anti-bcr-abl siRNAs on bcr-abl mRNA expression in bcr-abl-positive cells
| Cell sample/siRNA . | bcr-abl/GAPDH, % . | c-bcr/GAPDH, % . | c-abl/GAPDH, % . |
|---|---|---|---|
| K562 cells | |||
| GL2 | 99.7 ± 2.1 | 82.0 ± 13 | 97.5 ± 2.5 |
| GL2_inv | 98.0 ± 2.1 | 116 ± 13 | 102 ± 2.5 |
| b3a2_1 | 24.8 ± 3.7 | 98.0 ± 2.5 | 95.0 ± 10 |
| b3a2_3 | 32.4 ± 1.2 | 99.5 ± 2.2 | 109 ± 1.5 |
| CML-PBMNCs | |||
| GL2 | 100 | ND | ND |
| b3a2_1 | |||
| No. 1 | 21 | ND | ND |
| No. 2 | 45 | ND | ND |
| No. 3 | 46 | ND | ND |
| No. 4 | 45 | ND | ND |
| CML-CD34+cells | |||
| GL2 | 100 | 100 | 100 |
| b3a2_1 | |||
| No. 5 | 22 | 102 | 98 |
| No. 6 | 50 | 104 | 92 |
| Cell sample/siRNA . | bcr-abl/GAPDH, % . | c-bcr/GAPDH, % . | c-abl/GAPDH, % . |
|---|---|---|---|
| K562 cells | |||
| GL2 | 99.7 ± 2.1 | 82.0 ± 13 | 97.5 ± 2.5 |
| GL2_inv | 98.0 ± 2.1 | 116 ± 13 | 102 ± 2.5 |
| b3a2_1 | 24.8 ± 3.7 | 98.0 ± 2.5 | 95.0 ± 10 |
| b3a2_3 | 32.4 ± 1.2 | 99.5 ± 2.2 | 109 ± 1.5 |
| CML-PBMNCs | |||
| GL2 | 100 | ND | ND |
| b3a2_1 | |||
| No. 1 | 21 | ND | ND |
| No. 2 | 45 | ND | ND |
| No. 3 | 46 | ND | ND |
| No. 4 | 45 | ND | ND |
| CML-CD34+cells | |||
| GL2 | 100 | 100 | 100 |
| b3a2_1 | |||
| No. 5 | 22 | 102 | 98 |
| No. 6 | 50 | 104 | 92 |
The data represent normalized bcr-abl, c-bcr, and c-abl values from K562 cells, primary PBMNCs, and purified CD34+ CML cells 24 hours after electroporation with the respective siRNAs. GL2-siRNA controls (GL2) for each patient were set at 100%. K562 data represent mean ± SD from 4 independent experiments.
ND indicates not done.